Clinical trials with glimepiride

Charles M. Clark, Ahdy Helmy

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Data from 21 placebo-controlled, active-controlled or noncomparative studies involving more than 6500 patients, more than 4220 of whom were treated with glimepiride, are reviewed. Glimepiride has a rapid onset of action and is effective at a single daily dose. It is equally effective as the other second-generation sulfonylureas at doses of 1-8 mg/day, with doses above 4 mg/day reserved for patients with initial HbA(1c) above 8%. Glimepiride (at doses yielding the same blood-lowering effect as glyburide and glipizide), has a safety profile somewhat superior to that of glyburide, glipizide and gliclazide at a lower mg/day dose. Glimepiride also has been shown to be safe and effective in combination with insulin. Finally, glimepiride has two pharmacologic properties which have theoretical advantages over the other currently available sulfonylureas, but which have not as yet been shown to be clinically significant: it does not activate the cardiovascular K(ATP) channel and it achieves equivalent metabolic control at lower insulin secretion levels than the other sulfonylureas.

Original languageEnglish (US)
Pages (from-to)401-408
Number of pages8
JournalDrugs of Today
Volume34
Issue number5
StatePublished - 1998

Fingerprint

glimepiride
Clinical Trials
Glipizide
Glyburide
Gliclazide
Metabolic Equivalent
Insulin
Adenosine Triphosphate
Placebos
Safety

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Clark, C. M., & Helmy, A. (1998). Clinical trials with glimepiride. Drugs of Today, 34(5), 401-408.

Clinical trials with glimepiride. / Clark, Charles M.; Helmy, Ahdy.

In: Drugs of Today, Vol. 34, No. 5, 1998, p. 401-408.

Research output: Contribution to journalReview article

Clark, CM & Helmy, A 1998, 'Clinical trials with glimepiride', Drugs of Today, vol. 34, no. 5, pp. 401-408.
Clark, Charles M. ; Helmy, Ahdy. / Clinical trials with glimepiride. In: Drugs of Today. 1998 ; Vol. 34, No. 5. pp. 401-408.
@article{2f44dd551227489bb2265326d3abb082,
title = "Clinical trials with glimepiride",
abstract = "Data from 21 placebo-controlled, active-controlled or noncomparative studies involving more than 6500 patients, more than 4220 of whom were treated with glimepiride, are reviewed. Glimepiride has a rapid onset of action and is effective at a single daily dose. It is equally effective as the other second-generation sulfonylureas at doses of 1-8 mg/day, with doses above 4 mg/day reserved for patients with initial HbA(1c) above 8{\%}. Glimepiride (at doses yielding the same blood-lowering effect as glyburide and glipizide), has a safety profile somewhat superior to that of glyburide, glipizide and gliclazide at a lower mg/day dose. Glimepiride also has been shown to be safe and effective in combination with insulin. Finally, glimepiride has two pharmacologic properties which have theoretical advantages over the other currently available sulfonylureas, but which have not as yet been shown to be clinically significant: it does not activate the cardiovascular K(ATP) channel and it achieves equivalent metabolic control at lower insulin secretion levels than the other sulfonylureas.",
author = "Clark, {Charles M.} and Ahdy Helmy",
year = "1998",
language = "English (US)",
volume = "34",
pages = "401--408",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "5",

}

TY - JOUR

T1 - Clinical trials with glimepiride

AU - Clark, Charles M.

AU - Helmy, Ahdy

PY - 1998

Y1 - 1998

N2 - Data from 21 placebo-controlled, active-controlled or noncomparative studies involving more than 6500 patients, more than 4220 of whom were treated with glimepiride, are reviewed. Glimepiride has a rapid onset of action and is effective at a single daily dose. It is equally effective as the other second-generation sulfonylureas at doses of 1-8 mg/day, with doses above 4 mg/day reserved for patients with initial HbA(1c) above 8%. Glimepiride (at doses yielding the same blood-lowering effect as glyburide and glipizide), has a safety profile somewhat superior to that of glyburide, glipizide and gliclazide at a lower mg/day dose. Glimepiride also has been shown to be safe and effective in combination with insulin. Finally, glimepiride has two pharmacologic properties which have theoretical advantages over the other currently available sulfonylureas, but which have not as yet been shown to be clinically significant: it does not activate the cardiovascular K(ATP) channel and it achieves equivalent metabolic control at lower insulin secretion levels than the other sulfonylureas.

AB - Data from 21 placebo-controlled, active-controlled or noncomparative studies involving more than 6500 patients, more than 4220 of whom were treated with glimepiride, are reviewed. Glimepiride has a rapid onset of action and is effective at a single daily dose. It is equally effective as the other second-generation sulfonylureas at doses of 1-8 mg/day, with doses above 4 mg/day reserved for patients with initial HbA(1c) above 8%. Glimepiride (at doses yielding the same blood-lowering effect as glyburide and glipizide), has a safety profile somewhat superior to that of glyburide, glipizide and gliclazide at a lower mg/day dose. Glimepiride also has been shown to be safe and effective in combination with insulin. Finally, glimepiride has two pharmacologic properties which have theoretical advantages over the other currently available sulfonylureas, but which have not as yet been shown to be clinically significant: it does not activate the cardiovascular K(ATP) channel and it achieves equivalent metabolic control at lower insulin secretion levels than the other sulfonylureas.

UR - http://www.scopus.com/inward/record.url?scp=7144253807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7144253807&partnerID=8YFLogxK

M3 - Review article

C2 - 15010703

AN - SCOPUS:7144253807

VL - 34

SP - 401

EP - 408

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 5

ER -